^
over1year
Two detection methods of clinical KRAS G12C mutation detection for companion diagnostics (AACR 2023)
The FDA approved sotorasib, a KRAS G12C inhibitor, for targeted treatment of patients with KRAS G12C-mutated locally or metastatic non-small cell lung cancer (NSCLC)...Our methods are especially valuable for labs that appreciate simple, economical, yet sensitive companion diagnostics assays for KRAS G12C mutation. QClamp® assays can be easily adapted to detect other single gene mutations with high sensitivity for companion diagnostics use or other mutation detection applications.
Clinical • Companion diagnostic
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
QClamp® KRAS Mutation Detection Test
|
Lumakras (sotorasib)
2years
The ColoScape Test: A Novel QClamp XNA TechnologyBased Assay to Detect Colorectal Cancer Associated Mutations and Methylations in Plasma Cell-Free DNA (AMP 2022)
The ColoScape test utilizing the XNA-based technology provides high sensitivity and high specificity to CRC and advanced adenomas with a great potential to be used as an early screening test.
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
|
TP53 mutation • KRAS mutation • BRAF mutation • PIK3CA mutation
|
ColoScape™ Colorectal Cancer Mutation Detection Test • QClamp® BRAF Mutation Detection Test • QClamp® KRAS Mutation Detection Test • QClamp® NRAS Mutation Detection Kit • QClamp® PIK3CA Mutation Detection Test
almost3years
Circulating tumor DNA-based early detection of precancerous colorectal lesions using QClamp XNA-mediated real-time PCR. (PubMed, Pharmazie)
Most mutations occurred at APC876. The four genes' panel detected by XNA-based PCR technique might be suited to efficiently and micro-invasively detect genetic alterations in cfDNA of patients with precancerous colorectal lesions.
Journal • Circulating tumor DNA
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
|
KRAS mutation • BRAF mutation • APC mutation • CTNNB1 mutation
|
QClamp® BRAF Mutation Detection Test • QClamp® KRAS Mutation Detection Test